Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction
8. Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction
Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction
作者: M. V. Zhuravleva et al. 年份: 2024 期刊: Russian Journal of Cardiology DOI: 10.15829/1560-4071-2024-6027
证据等级: 待评估 IF: 待补充
中文核心摘要（150 字以内）：
目的。评估达格列净作为射血分数降低 (HFrEF) < 40% 的心力衰竭 (HF) 患者的各种治疗方案的一部分，这些患者在联邦优惠药物计划内接受药物治疗，以实现国家计划“医疗保健发展”的“降低心血管死亡率”。估算每 10 万人中心血管死亡率降低 1 例以及实现“心血管死亡率降低”目标指标 1 个百...
关键词：Jarvik-2000, 待补充
🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX
📖 英文原文摘要
英文摘要待补充
最后更新：2026-02-22 🔝 返回顶部